CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in <i>KRAS</i> wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial
Cancer communications